

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BCCA treatment protocols located at <a href="www.bccancer.bc.ca">www.bccancer.bc.ca</a> and according to acceptable standards of care

PROTOCOL CODE: BRAVNAV

DOCTOR'S ORDERS Htcm Wtk	g BS/	Am²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form		
DATE: To be given: Cycle #:		
Date of Previous Cycle:		
□ Delay Treatment week(s) □ CBC & Diff, Platelets day of treatment  May proceed with doses as written if within 24 hours ANC greater than or equal to 1.5 x 10 <sup>9</sup> /L, Platelets greater than or equal to 90 x 10 <sup>9</sup> /L  Dose modification for: □ Hematology □ ECOG □ Other Toxicity  Proceed with treatment based on blood work from		
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm		
<ul> <li>□ Prochlorperazine 10 mg PO prior to treatment</li> <li>□ Metoclopramide 10 – 20 mg PO prior to treatment</li> <li>□ Hydrocortisone 100 mg IV in 50 mL NS over 20 minutes pre-Vinorelbine (for patients who have had previous phlebitis)</li> <li>□ Other:</li> </ul>		
CHEMOTHERAPY:		
DAY 1 and 8		
Vinorelbine 30 mg/m²/day or 25 mg/m²/day (circle one) x BSA =mg  Dose Modification:% =mg/m²/day x BSA =mg  IV in 50 mL NS over 6 minutes on Day 1 and Day 8. Flush vein with 75 to 125 mL NS following infusion of Vinorelbine		
OR		
DOSE MODIFICATION REQUIRED ON DAY 8		
Vinorelbine 30 mg/m²/day or 25 mg/m²/day (circle one) x BSA =mg  Dose Modification: % = mg/m²/day x BSA = mg  IV in 50 mL NS over 6 minutes. Flush vein with 75 to 125 mL NS following infusion of Vinorelbine		
RETURN APPOINTMENT ORDERS		
Return in three weeks for Doctor and Cycle Book chemo room Day 1 and Date Last Cycle. Return inweeks.	ay 8	
CBC & Diff, platelets prior to each treatment If clinically indicated:   Bilirubin  Other tests:		
☐ Consults:		
☐ See general orders sheet for additional requests.		
DOCTOR'S SIGNATURE:	,	SIGNATURE:
	ı	UC: